June 17, 2021

Download Ebook Free Vaccines For Cancer Immunotherapy

Vaccines for Cancer Immunotherapy

Vaccines for Cancer Immunotherapy
Author : Nima Rezaei,Mahsa Keshavarz-Fathi
Publisher : Academic Press
Release Date : 2018-10-17
Category : Medical
Total pages :198
GET BOOK

Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines. Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer Presents the status of past and current vaccines for cancer treatment Considers advantages and disadvantages of different therapeutic cancer vaccines Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods Analyzes obstacles to development of therapeutic cancer vaccines Gives a view on future perspectives in the application of therapeutic cancer vaccines

Carbohydrate-Based Vaccines and Immunotherapies

Carbohydrate-Based Vaccines and Immunotherapies
Author : Zhongwu Guo,Geert-Jan Boons
Publisher : John Wiley & Sons
Release Date : 2009-06-09
Category : Science
Total pages :442
GET BOOK

The fundamental science and the latest developments in carbohydrate-based vaccines The relatively new field of glycoimmunology has emerged from the marriage of glycobiology and immunology, in recognition of the important role carbohydrates play as antigenic determinants. Carbohydrate-Based Vaccines and Immunotherapies comprehensively reviews the state of this exciting field, offering a single source for both the fundamental science and the latest developments. With contributions by leading experts, this resource covers the design, synthesis, evaluation, and applications of various carbohydrate-based vaccines, including polysaccharides, neoglycoproteins, and neoglycolipids. The text approaches vaccine design from a chemical and molecular focus, staying in line with current advances. Key topics covered by Carbohydrate-Based Vaccines and Immunotherapies include: Recent developments towards clinically useful vaccines against bacteria, viruses, parasites, and fungi Using adjuvants to improve immunogenicity and/or immunological properties of vaccines Choosing and designing proper adjuvants for specific targets Abnormal carbohydrates expressed by tumors Carbohydrate-based therapeutic cancer vaccines or cancer immunotherapy Clinical trials results for synthetic cancer vaccines Glycoengineering of cell surface carborhydrates and its anticancer applications Using cell surface carbohydrates for disease diagnosis A single, convenient source of state-of-the-art information from leading authorities in the field, Carbohydrate-Based Vaccines and Immunotherapies is an essential reference for organic chemists and biochemists, academic researchers, and other students and professionals involved in vaccine design.

Cancer Immunotherapy

Cancer Immunotherapy
Author : Claire Hearnden,Ed C. Lavelle
Publisher : Elsevier Inc. Chapters
Release Date : 2013-06-04
Category : Medical
Total pages :684
GET BOOK

This chapter describes the types of adjuvants that are being investigated as potential cancer adjuvant candidates and those that are currently being used in vaccines against certain cancers.

Cancer Immunotherapy

Cancer Immunotherapy
Author : Gabriela R. Rossi,Nicholas N. Vahanian,W. Jay Ramsey,Charles J. Link
Publisher : Elsevier Inc. Chapters
Release Date : 2013-06-04
Category : Medical
Total pages :684
GET BOOK

The hyperacute rejection of a xenotransplant is characterized by a complement-antibody mediated immune response dependent on αGal epitopes. Animal studies confirm that αGal epitopes expressed on allogeneic tumor vaccines elicit a potent T-cell-dependent antitumor immunity. Based on these immunologic reactions, we hypothesized that the hyperacute rejection mechanism could be exploited to alter antigen processing resulting in a novel therapeutic approach to treat human malignancies. Clinical trials data confirm that an immediate hypersensitivity response directed toward a vaccine composed of genetically modified allogeneic tumor cells expressing the xenoantigen αGal (HyperAcute vaccines) constitutes a polyvalent tumor cell vaccine with signs of clinical efficacy, concomitant to eliciting both a humoral IgG response as well as T-cell-mediated antitumor immunity. This conceptually innovative immunotherapy degrades tumoral immune escape and portends a promising genetic engineering tactic for the cost-effective development of a generally applicable human cancer vaccine principle with minimal toxicity. Encouraging results support additional clinical immunotherapy studies using HyperAcute vaccines.

Particulate Based Vaccines for Cancer Immunotherapy

Particulate Based Vaccines for Cancer Immunotherapy
Author : Rodney Alexander Rosalia
Publisher : Unknown
Release Date : 2014
Category :
Total pages :285
GET BOOK

Cancer Immunotherapy

Cancer Immunotherapy
Author : Nicholas M. Durham,Charles G. Drake
Publisher : Elsevier Inc. Chapters
Release Date : 2013-06-04
Category : Medical
Total pages :684
GET BOOK

The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system’s ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.

Tumor Immunology and Immunotherapy

Tumor Immunology and Immunotherapy
Author : Robert C. Rees
Publisher : OUP Oxford
Release Date : 2014-05-29
Category : Medical
Total pages :496
GET BOOK

Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management. Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity. The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.

Cancer Immunotherapy

Cancer Immunotherapy
Author : Freda K. Stevenson,Gianfranco di Genova,Christian H. Ottensmeier,Natalia Savelyeva
Publisher : Elsevier Inc. Chapters
Release Date : 2013-06-04
Category : Medical
Total pages :684
GET BOOK

The goal of mobilizing the immune response against cancer in patients is ambitious, and, to even approach success, all the tools of modern genetics have been required. Tools are needed for three tasks: to profile cancer cells, to understand how they survive and proliferate, and to activate immune pathways able to circumvent tumor protective mechanisms and mediate successful attack. Gene-based vaccines incorporate tumor antigen sequences together with genes encoding molecules identified as critical for inducing responses. The vaccine backbones activate innate immunity and, provided T-cell help is co-induced, DNA vaccines overcome regulation and lead to high levels of CD8+ T-cell attack on tumors. Delivery of DNA vaccines to large animals and patients has required new thinking and strategies such as electroporation are now in the clinic. Clinically meaningful immune responses are being induced and the community is developing new ways of evaluating immune responses in patients and connecting these to clinical outcome.

Cancer Immunotherapy

Cancer Immunotherapy
Author : Jeffrey Schlom,James W. Hodge,Claudia Palena,John W. Greiner,Kwong-Yok Tsang,Benedetto Farsaci,Ravi A. Madan,James L. Gulley
Publisher : Elsevier Inc. Chapters
Release Date : 2013-06-04
Category : Medical
Total pages :684
GET BOOK

This article reviews progress made in the design and development of recombinant poxviral-based vaccines that express transgenes for tumor-associated antigens (TAAs) and human T-cell co-stimulatory molecules (designated TRICOM). The TRICOM vaccine platform consists of priming with a recombinant vaccinia (rV-) vector and multiple boosts with a replication defective fowlpox (rF-) vector. The rV, rF-PSA-TRICOM (PROSTVAC) has demonstrated survival benefit in randomized trials. rV, rF-CEA-MUC1-TRICOM (PANVAC) has demonstrated evidence of benefit in patients with colorectal, breast and ovarian cancers. Preclinical studies with TRICOM-based vaccines have demonstrated their ability to be used in combination with anti-CTLA4 monoclonal antibody, radiation, chemotherapeutics, and small molecule targeted therapies to enhance vaccine-mediated immune responses and antitumor activity. Randomized clinical studies have been completed, are ongoing, and are planned employing several of these TRICOM vaccine combination therapies. The importance of trial design in terms of patient population and clinical trial endpoint has been demonstrated in these studies.

Liposome-based Synthetic Long Peptide Vaccines for Cancer Immunotherapy

Liposome-based Synthetic Long Peptide Vaccines for Cancer Immunotherapy
Author : Anonim
Publisher : Unknown
Release Date : 2016
Category :
Total pages :174
GET BOOK

Development of Novel DNA Based Vaccines for Cancer Immunotherapy

Development of Novel DNA Based Vaccines for Cancer Immunotherapy
Author : Erica Barbara Wilson
Publisher : Unknown
Release Date : 2004
Category :
Total pages :129
GET BOOK

Cancer Vaccines

Cancer Vaccines
Author : Natalia Savelyeva,Christian Ottensmeier
Publisher : Springer
Release Date : 2017-07-10
Category : Medical
Total pages :210
GET BOOK

This volume focuses on the laboratory and clinical experience with targeting viral onco-antigens, while also reviewing the approaches to targeting self-cancer antigens in cancers of non-viral origin, where self-tolerance has been a challenge. It emphasizes the importance of selecting the right vaccine platform to induce a successful immune response against cancer antigens. In addition, the volume discusses the advances made with genetic vaccines, including recent advances with DNA vaccines and the rapid transition of mRNA vaccines from the laboratory to bedside. The new avenues opening up for cancer immunotherapy underline the importance of combinational approaches using cancer vaccines with costimulatory antibodies, which may dramatically improve cancer treatment. This book is intended for all translational researchers and clinicians who aspire to develop novel vaccination approaches for cancer patients with unmet clinical needs.

Advancements in Tumor Immunotherapy and Cancer Vaccines

Advancements in Tumor Immunotherapy and Cancer Vaccines
Author : Hilal Arnouk
Publisher : BoD – Books on Demand
Release Date : 2012-02-03
Category : Medical
Total pages :230
GET BOOK

Harnessing the potential of the human body's own immune system to attack malignant tumor cells has been the goal of many scientific investigators in recent years, with advances in cancer biology and immunology enabling cancer immunotherapy to become a reality. World-class bench and clinical researchers have joined forces to collaborate and review current developments and trends in cancer immunology for the purposes of this book, and the result is a promising review of contemporary clinical treatments. In each chapter the authors present the scientific basis behind such therapeutic approaches, including cancer vaccines with special focus on prostate cancer, melanoma and novel approaches utilizing both innate and adaptive immune responses.

Cancer Immunotherapy and Biological Cancer Treatments

Cancer Immunotherapy and Biological Cancer Treatments
Author : Hilal Arnouk
Publisher : BoD – Books on Demand
Release Date : 2019-11-13
Category : Medical
Total pages :112
GET BOOK

In recent years, biological cancer therapies, including immunotherapy, have moved from the bench to mainstream medical treatments of several types of cancer. The success of these treatments relies on innovative approaches to specifically interfere with molecular targets that are involved in the growth, progression, and spread of malignant cells, or to bypass the tumor evasion of the immune system utilizing the latest advances in cancer vaccine development, formulation, and delivery. This book presents an up-to-date overview of novel cancer biological and immunotherapeutic approaches, including cancer vaccines, mimetic vaccines, monoclonal antibodies, adoptive T-cell transfer, chimeric antigen receptor T- cells, tumor infiltrating lymphocytes, dendritic cells, natural killer cells, immune checkpoint inhibitors, laser ablation, and immune stimulating interstitial laser thermotherapy.

Immunotherapy of Cancer

Immunotherapy of Cancer
Author : Yoshiyuki Yamaguchi
Publisher : Springer
Release Date : 2016-02-22
Category : Medical
Total pages :358
GET BOOK

This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.